Published • loading... • Updated
SEZ6 Signal 3x Higher than Rivals in Small Cell Lung Cancer Tumors
A large RNA analysis found SEZ6 outpaced other ADC targets in SCLC and supported Whitehawk’s planned HWK-206 development, researchers said.
- On Saturday, Whitehawk Therapeutics presented real-world analysis at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, confirming SEZ6 is highly expressed in small cell lung cancer .
- SEZ6 serves as a transmembrane protein involved in neuronal development with high expression levels across neuroendocrine tumors, supporting its potential as a clinically meaningful target for antibody drug conjugate development.
- Comparative analysis shows SEZ6 expression in SCLC is at least 3-fold higher than other established targets including HER2, B7-H3, DLL3, PD-L1, and PD-1.
- An Investigational New Drug application for Whitehawk's SEZ6-directed ADC, HWK-206, is expected in mid-2026, utilizing a biparatopic design for improved internalization.
- Clinical development plans include a Phase 1 study starting in Q3 2026, while SEZ6 expression correlations with DLL3 indicate potential for future combination approaches with DLL3-targeted therapies.
Insights by Ground AI
43 Articles
43 Articles
Coverage Details
Total News Sources43
Leaning Left6Leaning Right4Center16Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
L 23%
C 62%
15%
Factuality
To view factuality data please Upgrade to Premium
